Missed a GLP-1 dose: what each label instructs
There is no single GLP-1 missed-dose rule. One label gives five days, two give four, and one gives no window at all and writes its instruction against the next scheduled dose instead. The four instructions are printed below, each from the label that issues it, in the label’s own words.
Ellis Brandt built this site’s grading methodology and maintains it. Instructions read from the dosage and administration section of each label. Last re-read 2026-09-04.
Not medical advice. Semaglutide and tirzepatide are prescription-only medicines, and whether one is appropriate for you is a question for a licensed clinician who knows your history. This page reports what the FDA-approved prescribing information says and nothing else; it is not written or reviewed by a clinician. See the medical disclaimer.
The four windows
| Ozempic | within 5 days |
|---|---|
| Wegovy injection | no window stated |
| Mounjaro | within 4 days |
| Zepbound | within 4 days |
Read 2026-09-04. The full instruction for each is on this page; the summary above is not a substitute for it.
The four instructions
| Label | What the label instructs | Minimum gap when the injection day changes |
|---|---|---|
| Ozempic | Administer as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. | At least 2 days, stated as more than 48 hours |
| Wegovy injection | If the next scheduled dose is more than 2 days away, administer as soon as possible. If it is less than 2 days away, do not administer the missed dose and resume on the regularly scheduled day. | Not stated in these terms on this label |
| Mounjaro | Administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. | At least 3 days, stated as 72 hours |
| Zepbound | Administer as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. | At least 3 days, stated as 72 hours |
The last column is a separate rule from the missed-dose rule and is easy to conflate with it. It governs deliberately moving the weekly injection day, not recovering a dose that was forgotten.
More than one missed dose
Only one of the four labels says what to do after a run of missed doses. Wegovy: “If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions”.
| Label | Rule after consecutive missed doses |
|---|---|
| Wegovy injection | Reinitiate dosage escalation at a lower dosage after 2 or more consecutive missed doses. |
| Ozempic | [needs citation] — the label gives a single-dose rule and states no re-escalation threshold. |
| Mounjaro | [needs citation] — the label gives a single-dose rule and states no re-escalation threshold. |
| Zepbound | [needs citation] — the label gives a single-dose rule and states no re-escalation threshold. |
Three markers on one table, and they are a finding rather than an oversight: the census is four labels read end to end, and three of them do not answer the question. That is a question for the prescriber, and this site will not answer it by borrowing Wegovy’s rule and applying it to a different molecule.
The oral forms have their own rule
Wegovy’s label also covers a tablet, taken once daily rather than once weekly, and its missed-dose instruction is different again and much simpler: “If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day.” A daily product has no five-day window to give.
Sources
| Label | Applicant on the label | SPL version | Label effective date | Where it was read |
|---|---|---|---|---|
| Ozempic (semaglutide) | Novo Nordisk Pharmaceutical Industries, LP | 20 | 2026-06-01 | DailyMed, set id adec4fd2-6858-4c99-91d4-531f5f2a2d79 |
| Wegovy (semaglutide) | Novo Nordisk Pharmaceutical Industries, LP | 19 | 2026-06-18 | DailyMed, set id ee06186f-2aa3-4990-a760-757579d8f77b |
| Mounjaro (tirzepatide) | Eli Lilly and Company | 40 | 2026-08-27 | DailyMed, set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0 |
| Zepbound (tirzepatide) | Eli Lilly and Company | 40 | 2026-08-28 | DailyMed, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b |
Each capture was checked against its own document title before anything was quoted from it, and a nonsense set id was fetched through the identical method in the same session as a control — it returned 404 with an empty body, so a document that returns is a document that exists.
Related, and read from the same four documents: the dose escalation schedules and what each label reports for side effects.
More, read from the same labels
- Semaglutide vs tirzepatidereading the label
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- Dose escalation schedulesreading the label
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesreading the label
What each label reports for nausea, vomiting, diarrhoea and constipation — and the sentence every label prints above those numbers.
- Drug interactionsreading the label
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlinereading the label
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Who should not take onereading the label
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.